JPS56127379A - Hydantoin amine compound - Google Patents

Hydantoin amine compound

Info

Publication number
JPS56127379A
JPS56127379A JP1886581A JP1886581A JPS56127379A JP S56127379 A JPS56127379 A JP S56127379A JP 1886581 A JP1886581 A JP 1886581A JP 1886581 A JP1886581 A JP 1886581A JP S56127379 A JPS56127379 A JP S56127379A
Authority
JP
Japan
Prior art keywords
compounds
hydantoin
analogs
amino
amine compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1886581A
Other languages
English (en)
Other versions
JPS6237636B2 (ja
Inventor
Saajiesu Reinhaado
Kooren Shiyunuu Rodonii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of JPS56127379A publication Critical patent/JPS56127379A/ja
Publication of JPS6237636B2 publication Critical patent/JPS6237636B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP1886581A 1980-02-12 1981-02-10 Hydantoin amine compound Granted JPS56127379A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/120,944 US4248882A (en) 1980-02-12 1980-02-12 Treating diabetes-associated complications with hydantoin amines

Publications (2)

Publication Number Publication Date
JPS56127379A true JPS56127379A (en) 1981-10-06
JPS6237636B2 JPS6237636B2 (ja) 1987-08-13

Family

ID=22393428

Family Applications (1)

Application Number Title Priority Date Filing Date
JP1886581A Granted JPS56127379A (en) 1980-02-12 1981-02-10 Hydantoin amine compound

Country Status (8)

Country Link
US (1) US4248882A (ja)
EP (1) EP0034063B1 (ja)
JP (1) JPS56127379A (ja)
AT (1) ATE3865T1 (ja)
DE (1) DE3160449D1 (ja)
DK (1) DK156400C (ja)
GR (1) GR73856B (ja)
IE (1) IE50895B1 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61197581A (ja) * 1985-02-26 1986-09-01 Eisai Co Ltd ヒダントイン誘導体
JPS63126881A (ja) * 1986-11-14 1988-05-30 Sanwa Kagaku Kenkyusho Co Ltd ヒダントイン誘導体、その塩、これらの製法並びに該化合物を有効成分とする糖尿病合併症の予防及び治療剤

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4490381A (en) * 1979-11-13 1984-12-25 Imperial Chemical Industries Plc 1'-Substituted spiro[imidazolidine-4,3'-indoline]2,2',5-triones
ATE10940T1 (de) * 1981-05-12 1985-01-15 Imperial Chemical Industries Plc Pyrrolderivate.
US4556670A (en) * 1982-12-06 1985-12-03 Pfizer Inc. Spiro-3-hetero-azolones for treatment of diabetic complications
US4474967A (en) * 1983-04-27 1984-10-02 Pfizer Inc. 8-Deutero and 8-tritio-substituted derivatives of D-4S-6-fluoro-spiro-[chroman-4,4'-imidazolidine]-2',5'-dione
US4464380A (en) * 1983-05-25 1984-08-07 Pfizer Inc. Imidazolidinedione derivatives
DK277484A (da) * 1983-06-23 1984-12-24 Hoffmann La Roche Thiazolidinderivater
ATE56007T1 (de) * 1984-06-22 1990-09-15 Beecham Group Plc Wirksame benzopyranverbindungen.
US4680306A (en) * 1984-07-20 1987-07-14 Pfizer Inc. Sprio-imidazolones for treatment of diabetes complications
ATE37371T1 (de) * 1984-08-20 1988-10-15 Pfizer Verfahren zur herstellung asymmetrischer hydantoine.
US4966911A (en) * 1984-11-20 1990-10-30 Washington Research Foundation Immunoregulatory agents
US5340829A (en) * 1984-11-20 1994-08-23 Washington Research Foundation Immunoregulatory agents
US4575507A (en) * 1985-05-29 1986-03-11 Pfizer Inc. Spiro-imidazolidines as aldose reductase inhibitors and their pharmaceutical use
US4762839A (en) * 1985-06-06 1988-08-09 Tanabe Seiyaku Co., Ltd. Quinazolinone copmpounds useful for the prophyloxis and treatment of diabetic complications
JPS63132889A (ja) * 1986-11-21 1988-06-04 Tanabe Seiyaku Co Ltd キナゾリノン誘導体
HU204832B (en) * 1987-09-04 1992-02-28 Pfizer Process for producing spiro-(imidazolidine-4,4'-pyrano/2,3-b/pyridine) derivatives and pharmaceutical compositions comprising same
US4952694A (en) * 1988-07-27 1990-08-28 Pfizer Inc. Novel resolution process for racemic spiro-hydantoins
EP0536119A4 (en) * 1989-02-10 1993-08-04 Washington Research Foundation Immunoregulatory agents
JP2678499B2 (ja) * 1989-08-09 1997-11-17 日本臓器製薬 株式会社 尿毒症毒素低下剤
JPH03215435A (ja) * 1990-01-12 1991-09-20 Sanwa Kagaku Kenkyusho Co Ltd アルドース還元酵素阻害剤を主成分とする潰瘍治療剤
UA76984C2 (en) * 2001-04-05 2006-10-16 Nissan Chemical Ind Ltd A method for preparing a 7-qunolinyl-3,5-dihydroxyhept-6-enoate
JP2006504701A (ja) * 2002-09-30 2006-02-09 マーク・エー・バビザイェフ 眼疾患の局所的治療方法、並びに、その治療用組成物及び治療用手段

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1135915B (de) * 1961-06-29 1962-09-06 Asta Werke Ag Chem Fab Verfahren zur Herstellung neuer, antikonvulsiv wirksamer Spirohydantoine
US3534037A (en) * 1968-05-10 1970-10-13 Smithkline Corp Spiro-(imidazolidine and pyrimidine-quinoline and cyclopropa(c)quinoline) compounds
US3821383A (en) * 1972-07-10 1974-06-28 Ayerst Mckenna & Harrison Compositions for and a method of treating diabetic complications
US4117230A (en) * 1976-10-18 1978-09-26 Pfizer Inc. Hydantoin derivatives as therapeutic agents
US4130714A (en) * 1977-05-23 1978-12-19 Pfizer Inc. Hydantoin therapeutic agents
US4177282A (en) * 1977-05-23 1979-12-04 Pfizer Inc. Hydantoin therapeutic agents
US4176185A (en) * 1979-01-22 1979-11-27 Pfizer Inc. Spiro-quinolylhydantoins
US4181729A (en) * 1979-03-21 1980-01-01 Pfizer Inc. Phenyl or phenoxy substituted spiro-imidazolidinedione derivatives

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61197581A (ja) * 1985-02-26 1986-09-01 Eisai Co Ltd ヒダントイン誘導体
JPS63126881A (ja) * 1986-11-14 1988-05-30 Sanwa Kagaku Kenkyusho Co Ltd ヒダントイン誘導体、その塩、これらの製法並びに該化合物を有効成分とする糖尿病合併症の予防及び治療剤

Also Published As

Publication number Publication date
ATE3865T1 (de) 1983-07-15
IE50895B1 (en) 1986-08-06
DK56581A (da) 1981-08-13
DK156400B (da) 1989-08-14
EP0034063A1 (en) 1981-08-19
US4248882A (en) 1981-02-03
DE3160449D1 (en) 1983-07-28
EP0034063B1 (en) 1983-06-22
IE810261L (en) 1981-08-12
GR73856B (ja) 1984-05-08
DK156400C (da) 1990-01-08
JPS6237636B2 (ja) 1987-08-13

Similar Documents

Publication Publication Date Title
JPS56127379A (en) Hydantoin amine compound
DK0564924T3 (da) 2-Oxoethylderivater som immunosuppressiva
HU9600962D0 (en) Tricyclic carbamate compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
IE790088L (en) Thienohydantoin derivatives
ES486007A1 (es) Un procedimiento de preparacion de un derivado de espiro- policicloimidazolidindiona
AU581442B2 (en) 2-substituted-1, 3-propylidenediphosphonate derivatives, the process for their preparation and pharmaceutical compositions containing them
ZA85327B (en) Therapeutic compounds
AU5801286A (en) Spiro-imidazolidines as aldose reductase inhibitors
CA2030346A1 (en) Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds
SE8500387D0 (sv) Hydantoinderivat
AU670491B2 (en) Pharmaceutical for the treatment of skin disorders
IE800109L (en) Spiro-quinolylhydantoins
IE800672L (en) Spiro-quinolone hydantoins
EP0117035A3 (en) Aldose reductase inhibiting 5-(2-alkoxyphenyl)thiazolidinediones
AU639322B2 (en) Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds
GR3022217T3 (en) Treatment of cataract with prostacyclin compounds
ES8504144A1 (es) Un procedimiento para la preparacion de una 5-(2-alcoxi-fenil 3-sustituido)hidantoina
DE3467166D1 (en) Spiro-succinimides for treatment of diabetes complications
ES8507119A1 (es) Procedimiento para la preparacion de un compuesto de 5-(fenil sustituido) hidantoina.